PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutical

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. SPY
7. RXST
8. SPGI
9. RIVN
10. BFH

Go back to PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutical
(NASDAQ: PRTC) Delayed: 17.42 --0 (-0%)
Previous Close $17.42    52 Week High $ 
Open $17.42    52 Week Low $ 
Day High $17.42    P/E N/A 
Day Low $17.42    EPS $ 
Volume 5,178       

(NASDAQ: PRTC) Delayed: 17.42 --0 (-0%)
Previous Close $17.42    52 Week High $ 
Open $17.42    52 Week Low $ 
Day High $17.42    P/E N/A 
Day Low $17.42    EPS $ 
Volume 5,178